Format

Send to

Choose Destination
Lancet Infect Dis. 2013 Sep;13(9):785-96. doi: 10.1016/S1473-3099(13)70190-7.

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Author information

1
Department of Medicine, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA. smunozprice@med.miami.edu

Abstract

Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.

PMID:
23969216
PMCID:
PMC4673667
DOI:
10.1016/S1473-3099(13)70190-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center